The research question guiding this review is, in adults with heart failure, how does the use of SGLT-2 inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) impact nursing care, disease management, and patient education? Heart failure (HF) is a complex disease, with treatments evolving continuously to improve patient outcomes. One such treatment approved in 2022 is SGLT-2 inhibitors, originally used for type 2 diabetes; these drugs have been found to reduce the risk of hospitalization and death of patients with HF. With changes in practice, nurses and healthcare teams need to be updated on information regarding the provision of effective and safe patient care. An integrative literature review was conducted through the EBSCO databases and PubMed using identified key terms. Inclusion criteria were human population, English language, and publication within the last 5 years ensuring inclusion of relevant information. This search strategy identified 136 results with 47 duplicates, resulting in the screening of 89 titles/abstracts. The review is ongoing, and characteristics of included publications will be extracted. Results will provide guidance to nurses on education. We expect topics related to additional monitoring for kidney disease and management in the context of multiple chronic conditions.
